JAGSNPHARMNSEJagsonpal Pharmaceuticals Limited· PharmaceuticalsMediumNeutral
Announced Mon, 18 May · 18:03 IST

Jagsonpal Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP

Kmp ResignedManagement Changes View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹198.94
prior close
₹201.07
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.2-0.5-1.5-1.3+0.1+6.6+5.1+3.9+4.1+3.5+3.0+7.1+12.1
Up moveDown movePending
AI summary

Mrs. Pallavi Dinodia Gupta has resigned as an Independent Director of Jagsonpal Pharmaceuticals Limited effective May 18, 2026. She cited personal reasons including increasing professional commitments, personal engagements, health considerations, and the need to balance her existing responsibilities. She confirmed there are no other material reasons for her resignation beyond those stated. With her departure, she also ceases to be a member of the Audit Committee, Corporate Social Responsibility Committee, and Chairperson of the Stakeholders Relationship Committee. Mrs. Gupta remains an Independent Director on the boards of IndiaMART InterMESH Limited, Voith Paper Fabrics India Limited, and Lumax Industries Limited.

Likely market impact

This resignation reduces the board's independent oversight capacity and creates a vacancy in key committee positions. The company will need to appoint a new Independent Director to maintain compliance with SEBI regulations. While the stated personal reasons and explicit no-material-reason confirmation are reassuring, the departure of an independent director can raise minor governance concerns for investors in the short term.